Result of AGM

Cambridge Antibody Tech Group PLC
04 February 2005


For further information contact:        Weber Shandwick Square Mile (Europe)
Cambridge Antibody Technology           Tel: [phone]
Tel: [phone]               Kevin Smith
Peter Chambre, Chief Executive Officer  Yvonne Alexander
John Aston, Chief Financial Officer     BMC Communications/The Trout Group (USA)
Rowena Gardner, Director of Corporate   Tel: [phone]
Communications
                                        Brad Miles, ext 17 (media)
                                        Brandon Lewis, ext 15 (investors)
                   

                     CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC
                 REPORTS OUTCOME OF 2005 ANNUAL GENERAL MEETING

Cambridge, UK...Cambridge Antibody Technology (LSE: CAT, NASDAQ: CATG) reports
that at its Annual General Meeting, held at 12:30 GMT on Friday 4 February 2005,
all resolutions were duly passed.

                                     -ENDS-

Notes to Editors
Cambridge Antibody Technology (CAT):

  • CAT is a biopharmaceutical company using its proprietary technologies
    and capabilities in human monoclonal antibodies for drug discovery and drug
    development. Based near Cambridge, England, CAT currently employs around 280
    people

  • CAT is a leader in the discovery and development of human therapeutic
    antibodies and has an advanced proprietary technology for rapidly isolating
    human monoclonal antibodies using phage display and ribosome display
    systems. CAT has extensive phage antibody libraries, currently incorporating
    more than 100 billion distinct antibodies. These libraries form the basis
    for the Company's strategy to develop a portfolio of antibody-based drugs.
  
  • Four CAT human therapeutic antibody products are now at various stages
    of clinical development, with one further product candidate in pre-clinical
    development.
   
  • HUMIRA, the leading CAT-derived antibody, isolated and optimised in
    collaboration with Abbott, has been approved for marketing as a treatment
    for rheumatoid arthritis in 51 countries.

  • Six further licensed CAT-derived human therapeutic antibodies are in
    clinical development by licensees, with four further licensed product
    candidates in pre-clinical development.

  • CAT has alliances with a number of pharmaceutical and biotechnology
    companies to discover, develop and commercialise human monoclonal
    antibody-based products.

  • On 22 November 2004, CAT announced a major strategic alliance with
    AstraZeneca to discover and develop human antibody therapeutics in
    inflammatory disorders.

  • CAT has a broad collaboration with Genzyme for the development and
    commercialisation of antibodies directed against TGF, a family of proteins
    associated with fibrosis and scarring. This collaboration has so far given
    rise to one antibody product candidate at clinical development stage, and
    one at pre-clinical development stage.

  • CAT has also licensed its proprietary technologies to several companies.
    CAT's licensees include: Abbott, Amgen, Chugai, Genzyme, Human Genome
    Sciences, Merck & Co, Pfizer and Wyeth Research.

  • CAT is listed on the London Stock Exchange and on NASDAQ. CAT raised
    £41m in its IPO in March 1997 and £93m in a secondary offering in March
    2000.

Application of the Safe Harbor of the Private Securities Litigation Reform Act
of 1995: This press release contains statements about Cambridge Antibody
Technology Group plc ("CAT") that are forward looking statements. All statements
other than statements of historical facts included in this press release may be
forward looking statements within the meaning of Section 21E of the Securities
Exchange Act of 1934. These forward looking statements are based on numerous
assumptions regarding the company's present and future business strategies and
the environment in which the company will operate in the future. Certain factors
that could cause the company's actual results, performance or achievements to
differ materially from those in the forward looking statements include: market
conditions, CAT's ability to enter into and maintain collaborative arrangements,
success of product candidates in clinical trials, regulatory developments and
competition. We caution investors not to place undue reliance on the forward
looking statements contained in this press release. These statements speak only
as of the date of this press release, and we undertake no obligation to update
or revise the statements.


                      This information is provided by RNS
            The company news service from the London Stock Exchange